3-alpha-Hydroxy Pravastatin

3-alpha-Hydroxy Pravastatin is a stereoisomeric impurity of Pravastatin, characterized by a hydroxyl group at the 3α-position of the fused dihydronaphthalene ring system. This sodium salt derivative retains the pyrrole-fused hydrogenated benzene core and terminal carboxylate but exhibits altered stereochemistry compared to the parent drug's 2S,3R configuration. The hydroxyl substitution at C3 introduces a distinct chiral center, disrupting the β-hydroxy acid pharmacophore critical for HMG-CoA reductase inhibition. Synthetically, this compound emerges as a byproduct during asymmetric hydrogenation steps in pravastatin production. Analytically, it functions as an HPLC reference standard for enantiomeric purity assessment in active pharmaceutical ingredient batches.